Key statistics
On Wednesday, Sagimet Biosciences Inc (0O2:DUS) closed at 3.64, -9.00% below its 52-week high of 4.00, set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.54 |
---|---|
High | 3.64 |
Low | 3.54 |
Bid | 3.74 |
Offer | 3.86 |
Previous close | 3.66 |
Average volume | 44.67 |
---|---|
Shares outstanding | 32.20m |
Free float | 26.35m |
P/E (TTM) | -- |
Market cap | 127.65m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 18:30 BST.
More ▼
Announcements
- Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
- Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
- Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
- Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
More ▼